Transition drops new diabetes drug

pharmafile | September 20, 2010 | News story | Research and Development Transition Therapeutics, diabetes, lilly 

Transition Therapeutics is to abandon trials of its new diabetes treatment TT-223 following disappointing trial results.

The Canadian biopharma company says a study of the drug combined with another investigational drug, Lilly’s GLP-1 analogue LY2189265, failed to reach efficacy endpoints.

The company says it is now abandoning the drug, but hopes that another drug it in-licensed and is co-developing with Lilly will prove more successful.

“Development of a disease modifying therapy for type II diabetes is a high risk endeavour, but one that is needed by the millions of people living with this disease. While TT-223 has shown efficacy through development, these results indicate that it does not have the product profile for a diabetes therapy.”

Advertisement

“We wish to acknowledge, our development partner, Lilly, and the many clinicians that have shown a deep commitment in working together with us on the development of TT-223,” said Dr Tony Cruz, chairman and chief executive of Transition.

TT-223 is an analogue of gastrin, a hormone which stimulates the production of gastric acid, but is also believed to help the production of new insulin-producing cells in the pancreas. The trial results did not, however, yield positive results, and underline once again the difficulty in advancing diabetes care.

The company’s other diabetes compound in-licensed from Lilly is TT401/402. The drug is an anti-glycaemic compound and is expected to enter phase I trials in the third quarter of 2011.

Andrew McConaghie

Related Content

MetP Pharma releases positive data on intranasal semaglutide administration

MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …

handshake_2

AOTI diabetic foot care therapy to be used by NHS

Effective from September 2025, AOTI’s Topical Wound Oxygen (TWO2) therapy has been awarded inclusion in …

Recce Pharmaceuticals reports positive phase 2 data for skin infection drug

Recce Pharmaceuticals have announced positive patient data from its phase 2 clinical trial into RECCE …

The Gateway to Local Adoption Series

Latest content